- Home
- FTRE
as 09-15-2025 4:00pm EST
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 701.9M | IPO Year: | N/A |
| Target Price: | $12.06 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.97 - $25.28 | Next Earning Date: | 11-07-2025 |
| Revenue: | $2,733,500,000 | Revenue Growth: | -0.53% |
| Revenue Growth (this year): | -0.09% | Revenue Growth (next year): | -0.59% |
Stock Insider Trading Activity of Fortrea Holdings Inc. (FTRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Sep 9 '25 | Sell | $10.23 | 3,156 | $32,285.88 | 58,770 | |
| Morais Mark A. | FTRE | Chief Operating Officer | Sep 9 '25 | Sell | $10.23 | 3,155 | $32,275.65 | 56,976 | |
| Hanson James S. | FTRE | General Counsel | Sep 9 '25 | Sell | $10.23 | 1,677 | $17,155.71 | 19,092 | |
| Parks Robert | FTRE | Chief Accounting Officer | Sep 9 '25 | Sell | $10.23 | 592 | $6,056.16 | 1,450 | |
| Russell Erin L | FTRE | Director | Sep 2 '25 | Buy | $10.15 | 9,854 | $100,018.10 | 9,854 | |
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Aug 19 '25 | Sell | $8.01 | 4,886 | $39,136.86 | 58,770 | |
| Morais Mark A. | FTRE | Chief Operating Officer | Aug 19 '25 | Sell | $8.01 | 4,886 | $39,136.86 | 56,976 | |
| NEUPERT PETER M | FTRE | N/A | Aug 11 '25 | Buy | $6.26 | 32,500 | $203,450.00 | 98,132 | |
| NEUPERT PETER M | FTRE | N/A | Aug 8 '25 | Buy | $6.79 | 30,000 | $203,700.00 | 98,132 |
Latest Fortrea Holdings Inc. News
FTRE Breaking Stock News: Dive into FTRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
5 days ago
Jefferies Raises Fortrea (FTRE) PT to $9.50 Amid Improved Biotech Funding
Zacks
3 months ago
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
Argus Research
3 months ago
FTRE: Rating decreased to a SELL
Simply Wall St.
3 months ago
Is It Time To Consider Buying Fortrea Holdings Inc. (NASDAQ:FTRE)?
GlobeNewswire
3 months ago
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
Zacks
3 months ago
FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?
TipRanks
3 months ago
Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
Compare FTRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FTRE Fortrea Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.